Mohan Lauren J, Daly Jacqueline S, Ryan Barbara M, Ramtoola Zebunnissa
a Division of Biology, Department of Anatomy , Royal College of Surgeons in Ireland , Dublin , Ireland.
b School of Pharmacy, Royal College of Surgeons in Ireland , Dublin , Ireland.
Scand J Gastroenterol. 2019 Jan;54(1):18-26. doi: 10.1080/00365521.2018.1563805. Epub 2019 Jan 24.
There have been major advancements in the treatment of inflammatory bowel disease (IBD) over the past three decades. However despite significant progress, the best available treatments continue to demonstrate variable efficacy in patients and are associated with adverse effects. Therefore there remains an unmet clinical need for ongoing therapeutic advances for IBD. In recent years nanomedicines have emerged as promising diagnostic and therapeutic tools. Nanoparticles in particular show promise to facilitate targeted oral drug delivery in IBD. Here we discuss the pitfalls of current therapies and explore the potential for nanoparticles to improve the treatment of IBD. This review examines the range of conventional and novel therapies which have benefited from nanoparticle-mediated delivery and highlights the proven therapeutic efficacy of this approach in preclinical models. These strategies under development represent a novel and innovative treatment for IBD.
在过去三十年中,炎症性肠病(IBD)的治疗取得了重大进展。然而,尽管取得了显著进展,但现有的最佳治疗方法在患者中仍显示出不同的疗效,并且伴有不良反应。因此,IBD持续的治疗进展仍存在未满足的临床需求。近年来,纳米药物已成为有前景的诊断和治疗工具。特别是纳米颗粒有望促进IBD的靶向口服给药。在此,我们讨论当前疗法的缺陷,并探讨纳米颗粒改善IBD治疗的潜力。本综述研究了受益于纳米颗粒介导递送的一系列传统和新型疗法,并强调了该方法在临床前模型中已证实的治疗效果。这些正在开发的策略代表了一种新颖且创新的IBD治疗方法。